Concord Biotech Limited (CONCORDBIO.NS)
INR 1490.6
(-1.84%)
INR 1490.6
(-1.84%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 3.08 Billion INR | 28.33% |
| 2022 | 2.4 Billion INR | 37.25% |
| 2021 | 1.74 Billion INR | -25.53% |
| 2020 | 2.34 Billion INR | 38.89% |
| 2019 | 1.69 Billion INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 595.93 Million INR | -37.28% |
| 2023 Q2 | 810.19 Million INR | 48.68% |
| 2023 Q4 | 950.16 Million INR | 22.49% |
| 2023 Q3 | 775.72 Million INR | -4.25% |
| 2023 FY | 3.08 Billion INR | 28.33% |
| 2023 Q1 | 544.94 Million INR | -40.44% |
| 2022 Q3 | 773.68 Million INR | 252.2% |
| 2022 FY | 2.4 Billion INR | 37.25% |
| 2022 Q4 | 914.9 Million INR | 18.25% |
| 2022 Q2 | 219.67 Million INR | 0.0% |
| 2021 FY | 1.74 Billion INR | -25.53% |
| 2020 FY | 2.34 Billion INR | 38.89% |
| 2019 FY | 1.69 Billion INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Biocon Limited | 10.22 Billion INR | 69.868% |
| Blue Jet Healthcare Limited | 1.63 Billion INR | -88.153% |
| Dishman Carbogen Amcis Limited | -1.53 Billion INR | 300.784% |
| Jubilant Ingrevia Limited | 1.82 Billion INR | -68.466% |
| Lyka Labs Limited | -24.89 Million INR | 12476.605% |
| Panacea Biotec Limited | -11.73 Million INR | 26366.257% |
| Piramal Pharma Limited | 178.2 Million INR | -1628.974% |
| SMS Lifesciences India Limited | 90.92 Million INR | -3288.43% |
| Supriya Lifescience Limited | 1.19 Billion INR | -158.662% |
| Syngene International Limited | 5.1 Billion INR | 39.588% |
| TAKE Solutions Limited | -1.19 Billion INR | 357.568% |
| Zota Health Care Limited | -143.47 Million INR | 2247.375% |